Compare POCI & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POCI | PLUR |
|---|---|---|
| Founded | 1982 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.6M | 31.5M |
| IPO Year | N/A | N/A |
| Metric | POCI | PLUR |
|---|---|---|
| Price | $4.21 | $3.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 11.4K | ★ 48.1K |
| Earning Date | 02-12-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,575,039.00 | $1,326,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.67 | ★ 121.74 |
| 52 Week Low | $3.77 | $2.82 |
| 52 Week High | $5.34 | $7.13 |
| Indicator | POCI | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 41.32 |
| Support Level | $4.13 | $2.90 |
| Resistance Level | $4.25 | $3.02 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 39.32 | 13.10 |
Precision Optics Corp Inc is engaged in designing, developing, and manufacturing advanced optical instruments. It manufactures medical products such as endoscopes and endocouplers which incorporate various optical technologies for use in a variety of minimally invasive surgical and diagnostic procedures. The company also produces endoscopes for various applications as well as designs and manufactures custom optical medical devices to satisfy customers' specific requirements. In addition, the company manufactures and sells components and assemblies specially designed for industrial and military use. The company earns the majority of its revenue from the United States.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.